NCT05669664
Testing the Anti-cancer Drug Darolutamide in Patients With Testosterone-Driven Salivary Gland Cancers
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
The 50 most recent of 68 versions: 36 with changes below, 14 re-verified with no change. See every version on ClinicalTrials.gov ↗
Notable Eligibility criteria shortened, about 10 words Show 5 more changesShow less
- Study completion pushed from Nov 30, 2026 to Nov 12, 2027
- Enrollment target: estimated 21 to confirmed 20
- Primary completion date changed from estimate of Nov 30, 2026 to Nov 12, 2026
- Secondary endpoints: details revised at 2 of 3 entries
- Site details revised at 3 of 27 sites
- Minor Study sites revised (27)v67
- Minor Study sites revised (27)v66
- Minor Primary and study completion moved earlier from Apr 11, 2027 to Nov 30, 2026v65
- Minor Trial status: Recruiting to Active, Not Recruiting
- Site details revised at 27 of 27 sites
Show 31 earlier versionsHide 31 earlier versions
- Minor Site details revised at 2 of 27 sitesv61
- Minor Site details revised at 2 of 27 sitesv60
- Study Identification, Study Statusv58
- Minor Site details revised at 1 of 27 sitesv55
- Minor Study sites: 26 to 27v54
- Minor Site details revised at 1 of 26 sitesv52
- Minor Interventions: Biopsy (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Darolutamide (Drug), Leuprolide Acetate (Drug)… to Biopsy Procedure (Procedure), Biospecimen Collection (Procedure), Computed Tomography (Procedure), Darolutamide (Drug), Leuprolide Acetate…v51
- Minor Study sites: 25 to 26v50
- Minor Study sites: 22 to 25v49
- Minor Enrollment target: 20 to 21v47
- Minor Site details revised at 1 of 22 sitesv45
- Minor Site details revised at 1 of 22 sitesv44
- Minor Site details revised at 1 of 22 sitesv43
- Minor Study sites: 21 to 22v42
- Minor Site details revised at 1 of 21 sitesv41
- Minor Study sites: 20 to 21v40
- Minor Site details revised at 1 of 20 sitesv39
- Minor Site details revised at 1 of 20 sitesv38
- Minor Study sites: 19 to 20v36
- Minor Site details revised at 1 of 19 sitesv34
- Minor Site contacts updated at 1 of 19 sitesv33
- Minor Site details revised at 1 of 19 sitesv32
- Minor Study sites revised (19)v31
- Minor Site contacts updated at 1 of 19 sitesv30
- Minor Study sites: 18 to 19v26
- Minor Study sites: 17 to 18v25
- Minor Study sites: 16 to 17v24
- Minor Study sites: 15 to 16v23
- Minor Study sites revised (15)v22
- Minor Start date changed from estimate of Jan 9, 2024 to Jul 20, 2023v20
- Minor Study sites: 14 to 15v19
- Notable: the plan changed
- Minor: routine updates
Endpoints
Primary
Best overall response (BOR)
Timeframe: Within 1 year of initiating treatment
Secondary (3)
Progression-free survival (PFS)
Overall survival (OS)
Incidence of adverse events (AEs)
Arms and interventions
Treatment (darolutamide, leuprolide acetate)Experimental
Patients receive darolutamide PO BID on days 1-28 of each cycle and leuprolide acetate IM every 4 or 12 weeks. Cycles repeat every 28 days in the absence of disease progression or unacceptable toxicity. Patients also undergo biopsy, collection of blood samples, and CT/MRI throughout the trial.
Procedures: Biopsy Procedure, Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging
Drugs: Darolutamide, Leuprolide Acetate
Sites
27 sites in 1 country